key: cord-0715462-7xpa1se6
authors: Shahein, Abdul R.; Young, Heather; Dalabih, Abdallah
title: Phlegmonous Ileocolitis as a Presentation of Post SARS-CoV-2 (COVID-19) Multisystem Inflammatory Syndrome in Children
date: 2020-12-17
journal: JPGN Rep
DOI: 10.1097/pg9.0000000000000040
sha: b46b6927b256754a8e5454fcebf0bbee59f5da35
doc_id: 715462
cord_uid: 7xpa1se6

nan

P hlegmonous inflammation of the alimentary tract is characterized by diffuse inflammatory infiltrates of the submucosa of a portion of the intestine. The inflammatory reaction could reach the serosal surface with subsequent development of peritonitis or septicemia (1) . SARS-CoV-2 is a novel virus responsible for COVID-19 that is causing a global pandemic causing mortality already in over half a million people around the world. In May 2020, the Center for Disease Control released a case definition for the newly described multisystem inflammatory syndrome in children (MIS-C) believed to be precipitated by COVID-19 that includes an individual aged <21 years presenting with fever ≥38.0°C for at least 24 hours, laboratory evidence of inflammation, evidence of clinically severe illness requiring hospitalization, and multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological); AND no plausible alternative diagnoses; AND positive for current or recent SARS-CoV-2 infection by real-time polymerase chain reaction (PCR), serology, or antigen test, or exposure to a suspected or confirmed COVID-19 case within the 4 weeks before the onset of symptoms. MIS-Cs pathophysiology remains unclear.

However, it appears to be a postinfectious hyperimmune response that may occur during or following asymptomatic or symptomatic infection (2) .

A 6-year-old male, undervaccinated and with a history of exposure to COVID-19, presented with acute onset high-grade fever, nonbilious nonbloody vomiting, periumbilical diffuse abdominal pain, and watery diarrhea. Patient symptoms worsened over the prior 7 days. His caregiver was diagnosed with symptomatic COVID-19 infection by PCR about 6-8 weeks before presentation. However, the patient had no symptoms and was not tested at that time. He had no history of gastrointestinal disease or weight loss prior to this illness.

On presentation, he complained of shortness of breath and fatigue. Physical examination revealed fever (104°F) and toxic appearance. He had tachycardia with a short self-resolved episode of heart rate over 200 beats/min and had muffled heart sounds. He showed tachypnea, intercoastal retraction, and diffuse abdominal tenderness without peritoneal signs. Computerized tomography (CT) scan of the abdomen and pelvis with contrast showed extensive phlegmonous changes in the right lower quadrant around the ileocecal junction and terminal ileal loops. The terminal ileal loops, cecum, and ascending colon had wall thickening and abnormal enhancement. The ileocecal valve was edematous and was protruding into the cecum. Multiple enlarged (up to 2 cm) reactive lymph nodes were seen at the base of the mesentery and right lower quadrant. The CT scan also showed retrocolonic positioning of the appendix with borderline wall thickness and minimal fat stranding around the appendix (Fig. 1A, B) .

Blood work revealed evidence of inflammation including elevated C-reactive protein, erythrocyte sedimentation rate, fibrinogen, procalcitonin, d-dimer, ferritin, and neutrophils, and reduced lymphocytes and albumin. Transthoracic echocardiogram showed mildly dilated left and right atrium, trivial mitral and tricuspid valve insufficiency, and moderately diminished left and right ventricular systolic function. The estimated left ventricular ejection fraction by volume was 33% with normal diameter coronaries. Chest X-ray was positive for pulmonary edema and signs of fluid overload. Infectious evaluation was positive for COVID-19 immunoglobulin G with negative nasopharyngeal PCR (Table 1) .

Our patient was treated with intravenous ceftriaxone and metronidazole, immunoglobulin (IVIG) (2 g/kg/dose) for 2 doses within 24 hours, and methylprednisolone (1 mg/kg/dose twice daily for 3 days). He required inotropic support with milrinone. After initiation of IVIG and steroids, the patient showed improvement in fever and other systemic symptoms, including abdominal pain and diarrhea. Repeat CT scan of the abdomen and pelvis with contrast after 7 days of therapy showed complete disappearance of the previously found ileocecal phlegmon (Fig. 1C ).

Our patient was diagnosed with MIS-C based on the Center for Disease Control's recently released case definition. Although he did not report symptoms of COVID-19 infection before the acute presentation with myocarditis and phlegmonous ileocolitis, he had a history of exposure and a positive serum COVID-19 Immunoglobulin G.

Phlegmonous inflammation of the alimentary tract is a unique presentation of the novel SARS-CoV-2 virus. Historically, this inflammation is hypothesized to be of bacterial origin, but its portal of entry and the pathogenesis remains unclear. Phlegmon is often seen with Crohn's disease of the intestine. However, our patient did not report chronic gastrointestinal symptoms, and stool studies showed white blood cells count within normal limits. Mimics of inflammatory bowel disease (IBD) include not only infectious causes of colitis, but also vascular diseases, radiation-related injuries, druginduced inflammation, and monogenic disorders in very-early-onset refractory IBD. A superinfection with cytomegalovirus or Clostridium difficile can aggravate intestinal inflammation in IBD, especially in patients who are immunocompromised (4, 5) . Our patient had a negative comprehensive infectious evaluation (Table 1) , except for positive COVID-19 IgG which indicates a previous infection that occurred prior to presentation.

In conclusion, this is the first reported case of phlegmonous ileocolitis secondary to initially asymptomatic COVID-19 infection. It is prudent for physicians including gastroenterologists during the COVID-19 era to be aware of this unique presentation of the novel virus to avoid unnecessary or invasive surgical intervention.

Phlegmonous colitis

Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Pathological mimics of chronic inflammatory bowel disease

Differential diagnosis of inflammatory bowel disease: imitations and complications

Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children